Larotrectinib Shows Promise for Patients With NTRK-fusion Sarcoma

Share this content:
Researchers enrolled 11 patients with infantile fibrosarcoma or another sarcoma subtype to receive larotrectinib followed by surgery.
Researchers enrolled 11 patients with infantile fibrosarcoma or another sarcoma subtype to receive larotrectinib followed by surgery.
The following article features coverage from the Connective Tissue Oncology Society (CTOS) in Maui, Hawaii. Click here to read more of Cancer Therapy Advisor's conference coverage.

Larotrectinib, an orally administered TRK inhibitor, appears to be safe and effective in patients with locally advanced, NTRK-fusion cancers, including pediatric patients with infantile fibrosarcoma, according to an oral presentation at the Connective Tissue Oncology Society (CTOS) 2017 Annual Meeting.1

NTRK fusion is associated with several cancers, including infantile fibrosarcoma, which can require amputation or morbid surgery when disease is locally advanced. For this phase 1/2 trial (ClinicalTrials.gov Identifier: NCT02637687), researchers enrolled 11 patients with infantile fibrosarcoma (7 patients) or another sarcoma subtype (4 patients) to receive larotrectinib followed by surgery.

Ten (91%) patients had a partial response; 3 were referred to surgery after 4 to 6 cycles of larotrectinib. Two of these patients reached a complete response and are still disease-free.

Among patients who underwent surgery, no post-operative or healing complications were noted, suggesting that larotrectinib may prevent the need for amputation or morbid surgery.

The authors concluded that “patients with NTRK-fusion advanced sarcomas are able to proceed to surgical resection following pre-surgical [larotrectinib] without postoperative complications or wound healing issues.”

Final data will be presented at an upcoming meeting.

Read more of Cancer Therapy Advisor's coverage of the Connective Tissue Oncology Society (CTOS) by visiting the conference page.

Reference

  1. DuBois SG, Laetsch TW, Federman N, et al. The use of larotrectinib in the management of locally advanced pediatric NTRK-fusion sarcoma. Oral presentation at: Connective Tissue Oncology Society (CTOS) 2017 Annual Meeting. November 8-11, 2017; Maui, Hawaii.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs